Department of Error (DOI:10.1016/S0140-6736(07)61087-3);Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Lancet

Volumn 370, Issue 9582, 2007, Pages 143-152

  Seymour, Matthew T ^a   Maughan, Timothy S ^b   Ledermann, Jonathan A ^c   Topham, Clare ^d   James, Roger ^e   Gwyther, Stephen J ^f   Smith, David B ^g   Shepherd, Stephen ^h   Maraveyas, Anthony ⁱ   Ferry, David R ^j   Meade, Angela M ^k   Thompson, Lindsay ^k   Griffiths, Gareth O ^k   Parmar, Mahesh KB ^k   Stephens, Richard J ^k  

^a United Kingdom   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d St Lukes Surgery   (United Kingdom)

^e Kent Oncology Centre   (United Kingdom)

^f EAST SURREY HOSPITAL   (United Kingdom)

^g CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^h CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

ⁱ Princess Royal Hospital Hull   (United Kingdom)

^j NEW CROSS HOSPITAL   (United Kingdom)

^k MEDICAL RESEARCH COUNCIL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; TREATMENT OUTCOME; VOMITING;

EID: 34447255724     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61294-X     Document Type: Erratum

References (32)

1. Worldwide Cancer Mortality Statistics. World Health Organization and International Agency for Research on Cancer databank. GLOBOCAN 2002. http://www-dep.iarc.fr (accessed June 28, 2007).
2. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16 (1998) 301-308
3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10 (1992) 896-903
4. de Gramont A., Bosset J., Milan C., et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 15 (1997) 808-815
5. Cao S., and Rustum Y. Synergistic antitumour activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60 (2000) 3717-3721
6. Fischel J., Etienne M., Formento P., and Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 10 (1998) 2529-2535
7. Cunningham D., Pyrhonen S., James R., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
8. Douillard J., Cunningham D., Roth A., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
9. Saltz L., Cox J., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
10. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
11. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
12. Rothenberg M., Oza A., Bigelow R., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 (2003) 2059-2069
13. Grothey A., Sargent D., Goldberg R., and Schmoll H. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
14. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus Irinotecan, fluorouracil, and leucovorin for Metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
15. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and centuximab plus Irinotecan in Irinotecan-refractory Metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
16. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. World Health Organization. WHO handbook for reporting results of cancer treatment: WHO offset publication number 48 (1979), WHO, Geneva
18. Cheeseman S., Joel S., Chester J., et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87 (2002) 393-399
19. Leonard P., Seymour M., James R., Hochhauser D., and Ledermann J. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 87 (2002) 1216-1220
20. Maughan T., James R., Kerr D., et al., Medical Research Council Colorectal Cancer Group. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361 (2003) 457-464
21. Chester J., Dent J., Wilson G., Ride E., and Seymour M. Protracted infusional 5-fluorouracil with bolus Mitomycin in 5FU-resistant colorectal cancer. Ann Oncol 11 (2000) 235-237
22. Burge M., Smith D., Topham C., et al. A phase I and II study of 2-weekly Irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer 94 (2006) 1281-1286
23. MRC Good Research Practice (2005), Medical Research Council, London. http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC002415 (accessed June 28, 2007).
24. Aaronson N., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
25. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
26. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
27. National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Technology appraisal number 33, March 2002.
28. Goldberg R., Sargent D., Morton R., et al. A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
29. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22 (2004) 229-237
30. Braun M., Richman S., Adlard J., et al., and the FOCUS Trial Investigators. Association of topoisomerase-1 (Topo1) with the efficacy of chemotherapy in a randomized trial for advanced colorectal cancer patients (FOCUS). J Clin Oncol 24 suppl (2006) 10009
31. Pluzanska A., Mainwaring P., Cassidy J., et al. Final results of a randomised phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study). J Clin Oncol 23 suppl (2005) 3517
32. Hurwitz H., Fehrenbacher L., Hainsworth J., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508